Mon Jul 14 03:50:00 UTC 2025: **News Article: Anthem Biosciences Secures ₹1,016 Crore from Anchor Investors Ahead of IPO**

**Bengaluru, India** – Anthem Biosciences, a Bengaluru-based Contract Research, Development, and Manufacturing Organisation (CRDMO), has successfully raised ₹1,016 crore from anchor investors in anticipation of its Initial Public Offering (IPO) set to open for public subscription on July 14.

The company allotted 1.78 crore equity shares to 60 anchor investors at ₹570 per share, the upper end of the IPO’s price band. The anchor book saw strong participation from both global and domestic institutional investors. Specific names were not released.

The IPO is an Offer For Sale (OFS) by promoters, investors, and other personnel, meaning Anthem Biosciences will not receive any proceeds from the offering. The price band for the IPO has been fixed between ₹540 and ₹570 per share. Investors can apply for a minimum lot size of 26 shares, and in multiples thereof.

Anthem Biosciences has demonstrated solid financial performance, reporting a revenue of ₹1,844 crore in FY25, a 30% year-on-year increase from ₹1,419 crore in FY24. Profit after tax (PAT) also saw a significant rise of 23% to ₹451 crore during the same period.

The company will join a list of listed industry peers including Sai Life Sciences Limited, Syngene International, Suven Life Sciences, and Divi’s Laboratories.

JM Financial, Citigroup Global Markets India, JP Morgan India, and Nomura Financial Advisory and Securities (India) are acting as the book-running lead managers for the IPO. Kfin Technologies Limited has been appointed as the registrar for the issue.

Founded in 2006, Anthem Biosciences operates across the entire pharmaceutical value chain, encompassing drug discovery, development, and manufacturing. They also specialize in producing and marketing complex fermentation-based Active Pharmaceutical Ingredients (APIs) such as probiotics, enzymes, peptides, nutritional actives, vitamin analogues, and biosimilars.

Read More